Thalidomide in Total Therapy 2 Overcomes Inferior Prognosis of Myeloma with Low Expression of the Glucocorticoid Receptor Gene NR3C1

PURPOSE: Because dexamethasone remains a key component of myeloma therapy, we wished to examine the impact of baseline and relapse expression levels of the glucocorticoid receptor gene NR3C1 on survival outcomes in the context of treatment with or without thalidomide. EXPERIMENTAL DESIGN: We investi...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Heuck, Christoph J, Szymonifka, Jackie, Hansen, Emily, Shaughnessy, John D., Usmani, Saad Z, van Rhee, Frits, Anaissie, Elias, Nair, Bijay, Waheed, Sarah, Alsayed, Yazan, Petty, Nathan, Bailey, Clyde, Epstein, Joshua, Hoering, Antje, Crowley, John, Barlogie, Bart
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3677537/
https://ncbi.nlm.nih.gov/pubmed/22855579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0019
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk